$AFFX (Affymetrix Inc.)

$AFFX {{ '2016-03-21T15:45:52+0000' | timeago}} • Announcement

Maker of DNA microarrays $AFFX said that it has reviewed the proposal made by Origin Technologies Corporation, LLC on March 18 for a transaction where $AFFX stockholders would receive $16.10 per share in cash. $AFFX is precluded by terms of its $TMO merger agreement from negotiating with or giving out information to Origin regarding the proposal.

$PKI {{ '2017-07-24T21:21:06+0000' | timeago}} • Announcement

$PKI BoD declared a regular quarterly dividend of $0.07 per share of common stock on July 24, 2017. This dividend is payable on Nov. 10, 2017 to all shareholders of record at the close of business on Oct. 20, 2017.

$GE {{ '2017-07-21T18:59:39+0000' | timeago}} • Webcast

John Flannery, who is to be $GE's 13th CEO effective Aug 1, 2017, brushed aside concerns that the company might find itself in a state of limbo during the transition period. He said there is no operational paralysis within the team, adding robust discussions will happen in November regarding the future of course of $GE's operations.

$GE {{ '2017-07-21T18:13:06+0000' | timeago}} • Webcast

$GE reiterated its FY17 net earnings guidance of $1.60-1.70 per share on organic sales growth, which is expected in the range of 3-5%. The company added that EPS is trending to the bottom end of the projected range, as Oil and Gas continues to witness weakness.

$GE {{ '2017-07-21T17:28:46+0000' | timeago}} • Webcast

Cash flow from operations, one of $GE's closely watched financial metric, plummeted 67% to $3.6Bil in 2Q17. The Boston, Massachusetts-based conglomerate said this was primarily due to the sale of its appliances division.

$GE {{ '2017-07-21T12:51:53+0000' | timeago}} • Infographic

$GE General Electric Earnings AlphaGraphics: Q2 2017 highlights

$GE {{ '2017-07-21T11:43:55+0000' | timeago}} • Announcement

$GE CEO Jeff Immelt said, "We expect cash flow to continue to improve throughout the year. We’ve reduced our industrial structural costs year-to-date by $670MM and we are on track to meet or exceed our $1Bil cost reduction target for the year."

$GE {{ '2017-07-21T11:40:52+0000' | timeago}} • Announcement

Primarily due to $GE's shift of focus into industrial operations, its backlog in 2Q17 grew 2% to $327Bil, while orders increased 6% to $28.3Bil. $GE has a history of orders and backlogs growing faster than its revenue.

$GE {{ '2017-07-21T11:38:01+0000' | timeago}} • Announcement

$GE's total revenue in 2Q17 fell 12% to $29.6Bil due to weakness in its Energy Connections segment, which supplies automation products to various industries including marine, mining and oil & gas. Revenue from this segment fell 27% during the quarter.

$GE {{ '2017-07-21T11:35:13+0000' | timeago}} • Announcement

In 2Q17, which marks the end of Jeff Immelt at the helm of $GE after 16 years, the multinational conglomerate posted net earnings that more-than-halved to $1.19Bil, or $0.13 per share. On a non-GAAP basis, EPS declined 45% to $0.28 during the quarter.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$DHR {{ '2017-07-20T15:06:40+0000' | timeago}} • Webcast

With nearly $900MM of free cash flow and strong conversion in 2Q17, $DHR is optimistic on further acqusitions. Adding to its strong cash flow, $DHR has $500MM to $1Bil worth of opportunities slated for 2H17. Notably, the company's two most recent large acquisitions, Pall and Cepheid, continues to perform well and became part of the core revenue.

$DHR {{ '2017-07-20T13:00:10+0000' | timeago}} • Announcement

For 3Q17, $DHR sees its GAAP EPS to range from $0.74 to $0.78 and non-GAAP EPS to range from $0.92 to $0.96. For FY17, GAAP EPS to range from $3.16 to $3.23 and non-GAAP EPS to range from $3.90 to $3.97.

$DHR {{ '2017-07-20T12:56:52+0000' | timeago}} • Announcement

$DHR, a science and technology company, reported a 15% YoY drop in net earnings for 2Q17 to $557.3MM, or $0.79 per share. Earnings, adjusted for one-time gains and costs, grew 10% to $0.99 per share. Sales rose 6% to $4.5Bil.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$DHR {{ '2017-07-20T12:12:31+0000' | timeago}} • Infographic

$DHR Danaher Corp. Earnings AlphaGraphic: Q2 2017 Highlights

$NEM {{ '2017-07-19T20:55:03+0000' | timeago}} • Announcement

$NEM elected Sheri Hickok and Molly Zhang to its BoD. Hickok is currently General Manager, Global Product Development, Onshore Wind at $GE's Renewable Energy. Zhang currently serves as a director of Cooper Standard Automotive and XG Science as a supervisory board member at GEA Group in Germany.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

Recent Transcripts

GE (General Electric Company)
Friday, July 21 2017 - 12:30pm
SNA (Snap-on Incorporated)
Thursday, July 20 2017 - 2:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm
UQM (UQM Technologies Inc.)
Thursday, May 11 2017 - 8:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
COHR (Coherent Inc.)
Tuesday, May 9 2017 - 8:30pm
FLDM (Fluidigm Corporation)
Thursday, May 4 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
PKI (PerkinElmer Inc.)
Thursday, May 4 2017 - 9:00pm
PSDV (pSivida Corp.)
Thursday, May 4 2017 - 8:30pm
CBMX (CombiMatrix Corporation)
Thursday, May 4 2017 - 8:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
STS (Supreme Industries Inc.)
Monday, May 1 2017 - 1:00pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am
PACB (Pacific Biosciences of California, Inc.)
Wednesday, April 26 2017 - 8:30pm

AlphaGraphics you may like